20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Stoke Therapeutics Inc (STOK) operates in the BIOTECHNOLOGY industry and is headquartered in Bedford, United States with about 170 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, STOK reported $184M in revenue and ($7M) in net income.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Interactive charts & full statements → Open the STOK valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $28M | $184M | $37M | $9M | $12M | $3M | $0M | $0M | $0M | $0M |
| Gross Profit | $23M | $184M | $37M | $9M | $12M | ($2M) | ($2M) | $0M | $0M | $0M |
| Gross Margin % | 84.7% | 100.0% | 100.0% | 100.0% | 100.0% | -74.3% | — | — | — | — |
| Operating Income (EBIT) | ($223M) | ($21M) | ($101M) | ($115M) | ($104M) | ($86M) | ($53M) | ($36M) | ($13M) | ($6M) |
| Operating Margin % | -809.7% | -11.2% | -277.3% | -1307.2% | -841.2% | -2868.8% | — | — | — | — |
| Net Income | ($208M) | ($7M) | ($89M) | ($105M) | ($93M) | ($85M) | ($51M) | ($29M) | ($13M) | ($6M) |
| Net Margin % | -753.6% | -3.7% | -243.4% | -1192.5% | -750.6% | -2823.7% | — | — | — | — |
| EBITDA | ($205M) | ($5M) | ($87M) | ($102M) | ($103M) | ($85M) | ($52M) | ($35M) | ($13M) | ($5M) |
| Earnings Per Share (EPS) | $-3.37 | $-0.12 | $-1.65 | $-2.38 | $-2.39 | $-2.31 | $-1.51 | $-1.59 | $-0.53 | $-0.24 |
| Shares Outstanding (M) | 66M | 59M | 54M | 44M | 39M | 37M | 33M | 18M | 24M | 24M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $9M | $6M | $1M | $11M | $14M | $159M | $23M | $5M |
| Gross Profit | $8M | $5M | $0M | $10M | $14M | $159M | $23M | $5M |
| Gross Margin % | 87.8% | 83.2% | 24.8% | 90.7% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($65M) | ($53M) | ($61M) | ($43M) | ($27M) | $111M | ($14M) | ($30M) |
| Operating Margin % | -701.6% | -857.6% | -4382.2% | -405.3% | -197.6% | 70.2% | -60.4% | -613.1% |
| Net Income | ($62M) | ($50M) | ($58M) | ($38M) | ($23M) | $113M | ($10M) | ($26M) |
| Net Margin % | -660.8% | -802.8% | -4132.2% | -360.7% | -170.0% | 71.2% | -46.4% | -540.0% |
| EBITDA | ($64M) | ($46M) | ($57M) | ($39M) | ($23M) | $115M | ($10M) | ($26M) |
| Earnings Per Share (EPS) | $-0.93 | $-0.79 | $-0.99 | $-0.65 | $-0.40 | $1.90 | $-0.18 | $-0.47 |
| Shares Outstanding (M) | 66M | 63M | 58M | 59M | 58M | 59M | 57M | 56M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($178M) | $46M | ($87M) | ($81M) | ($32M) | ($67M) | ($42M) | ($31M) | ($11M) | ($5M) |
| Capital Expenditures (CapEx) | $3M | $1M | $0M | $2M | $4M | $1M | $1M | $2M | $1M | $0M |
| Free Cash Flow (FCF) | ($181M) | $45M | ($87M) | ($83M) | ($36M) | ($68M) | ($43M) | ($33M) | ($12M) | ($5M) |
| FCF Margin % | -654.9% | 24.3% | -238.2% | -941.7% | -288.8% | -2270.2% | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($57M) | ($61M) | ($30M) | ($30M) | ($25M) | $132M | ($23M) | ($22M) |
| Capital Expenditures (CapEx) | $2M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($59M) | ($61M) | ($31M) | ($30M) | ($26M) | $132M | ($23M) | ($22M) |
| FCF Margin % | -628.0% | -978.3% | -2188.7% | -286.9% | -185.1% | 83.0% | -102.8% | -443.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $394M | $418M | $272M | $228M | $256M | $239M | $298M | $229M | $108M | $2M |
| Cash & Cash Equivalents | $110M | $84M | $128M | $191M | $114M | $145M | $287M | $222M | $105M | $2M |
| Total Liabilities | $48M | $66M | $43M | $69M | $71M | $21M | $12M | $4M | $2M | $4M |
| Total Debt (Short + Long-Term) | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $0M | $0M | $3M |
| Total Shareholders' Equity | $346M | $352M | $229M | $160M | $185M | $218M | $286M | $224M | $105M | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive STOK viewer.
About TickerBase · Data methodology & sources · Privacy · Terms